News Releases

Alcresta Therapeutics Receives 510(K) Clearance For Use of RELiZORB® in Children

Jul 20, 2017

RELiZORB, The Only Digestive Enzyme Cartridge for Patients Requiring Supplemental Enteral Nutrition, Now Cleared to Help Children Suffering
From Fat Malabsorption

Alcresta Therapeutics’ RELiZORB™ Increases Fat Absorption in Adult and Pediatric Patients with Cystic Fibrosis Receiving Enteral Nutrition

Oct 28, 2016

RELiZORB significantly increased plasma levels of DHA and EPA fatty acids and patients report a decrease in the frequency and severity of gastrointestinal symptoms

RELiZORB™ Recognized for Medical Design Excellence

Jul 26, 2016

Alcresta Therapeutics’ RELiZORB, a first-of-its kind digestive enzyme cartridge designed to mimic the function of pancreatic lipase, was selected as the Gold Winner at the Medical Device Excellence Awards (MDEA).

Alcresta Therapeutics Launches RELiZORB™ in the U.S.

Jun 07, 2016

First Digestive Enzyme Cartridge Designed to Improve Digestion of Essential Fats in Enteral Tube Feeding 

Alcresta to Present at the 34th Annual J.P. Morgan Healthcare Conference

Jan 06, 2016

Corporate presentation at J.P. Morgan Healthcare Conference

Alcresta Receives FDA Clearance for RELiZORB™

Dec 02, 2015

First Digestive Enzyme Cartridge Designed for Patients on Enteral Feeding

Alcresta to Present at 29th Annual North American Cystic Fibrosis Conference

Oct 08, 2015

Expands Leadership Team in Preparation for Commercial Launch

Alcresta Presents New Data at 28th Annual North American Cystic Fibrosis Conference (NACFC)

Oct 23, 2014

Demonstrating Potential of Proprietary Enzyme-Based Technology to Improve Nutrition in Patients with Exocrine Pancreatic Insufficiency

Alcresta Announces Agreement with Cystic Fibrosis Foundation Therapeutics

Apr 17, 2014

Agreement Highlights Importance of Medical Nutrition in Managing Cystic Fibrosis

Alcresta Launches Innovative Enzyme-Based Nutritional Company

Apr 17, 2012

Proprietary Platform for Nutritional Products that Improve Health and Manage Disease; Founded with New Synergistic Business Model by Proven Team and Top-Tier VCs